Drug Trial Radar · NCT07762443
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 22, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).
Conditions
- Alopecia Areata
Interventions
VC005 tabletsDrug
VC005 repeat administration for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)Time frame: Day1,Day28
- Peak Plasma Concentration (Cmax)Time frame: Day1,Day28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.